Literature DB >> 21084862

Merlin's tumor suppression linked to inhibition of the E3 ubiquitin ligase CRL4 (DCAF1).

Wei Li1, Filippo G Giancotti.   

Abstract

The mechanism by which the FERM domain protein Merlin, encoded by the tumor suppressor NF2, restrains cell proliferation is poorly understood. Prior studies have suggested that Merlin exerts its antimitogenic effect by interacting with multiple signaling proteins located at or close to the plasma membrane. We have recently observed that Merlin translocates into the nucleus and binds to and inhibits the E3 ubiquitin ligase CRL4 (DCAF1) . Genetic evidence indicates that inactivation of Merlin induces oncogenic gene expression, hyperproliferation, and tumorigenicity by unleashing the activity of CRL4 (DCAF1) . In addition to providing a potential explanation for the diverse effects that loss of Merlin exerts in multiple cell types, these findings suggest that compounds inhibiting CRL4 (DCAF1) may display therapeutic efficacy in Neurofibromatosis type 2 and other cancers driven by Merlin inactivation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21084862      PMCID: PMC3048042          DOI: 10.4161/cc.9.22.13838

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  34 in total

1.  The FERM-domain protein Expanded regulates Hippo pathway activity via direct interactions with the transcriptional activator Yorkie.

Authors:  Caroline Badouel; Laura Gardano; Nancy Amin; Ankush Garg; Robyn Rosenfeld; Thierry Le Bihan; Helen McNeill
Journal:  Dev Cell       Date:  2009-03       Impact factor: 12.270

Review 2.  Improving the outcome in malignant pleural mesothelioma: nonaggressive or aggressive approach?

Authors:  Rolf A Stahel; Walter Weder
Journal:  Curr Opin Oncol       Date:  2009-03       Impact factor: 3.645

3.  Kibra functions as a tumor suppressor protein that regulates Hippo signaling in conjunction with Merlin and Expanded.

Authors:  Jianzhong Yu; Yonggang Zheng; Jixin Dong; Stephen Klusza; Wu-Min Deng; Duojia Pan
Journal:  Dev Cell       Date:  2010-02-16       Impact factor: 12.270

4.  Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling.

Authors:  Miguel A López-Lago; Tomoyo Okada; Miguel M Murillo; Nick Socci; Filippo G Giancotti
Journal:  Mol Cell Biol       Date:  2009-05-18       Impact factor: 4.272

5.  NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.

Authors:  Marianne F James; Sangyeul Han; Carolyn Polizzano; Scott R Plotkin; Brendan D Manning; Anat O Stemmer-Rachamimov; James F Gusella; Vijaya Ramesh
Journal:  Mol Cell Biol       Date:  2009-05-18       Impact factor: 4.272

6.  CUL4A abrogation augments DNA damage response and protection against skin carcinogenesis.

Authors:  Liren Liu; Sharrell Lee; Jianxuan Zhang; Sara B Peters; Jeffrey Hannah; Yue Zhang; Yan Yin; Andrew Koff; Liang Ma; Pengbo Zhou
Journal:  Mol Cell       Date:  2009-05-14       Impact factor: 17.970

7.  Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control.

Authors:  Bin Zhao; Xiaomu Wei; Weiquan Li; Ryan S Udan; Qian Yang; Joungmok Kim; Joe Xie; Tsuneo Ikenoue; Jindan Yu; Li Li; Pan Zheng; Keqiang Ye; Arul Chinnaiyan; Georg Halder; Zhi-Chun Lai; Kun-Liang Guan
Journal:  Genes Dev       Date:  2007-11-01       Impact factor: 11.361

8.  An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer.

Authors:  Teresa A Soucy; Peter G Smith; Michael A Milhollen; Allison J Berger; James M Gavin; Sharmila Adhikari; James E Brownell; Kristine E Burke; David P Cardin; Stephen Critchley; Courtney A Cullis; Amanda Doucette; James J Garnsey; Jeffrey L Gaulin; Rachel E Gershman; Anna R Lublinsky; Alice McDonald; Hirotake Mizutani; Usha Narayanan; Edward J Olhava; Stephane Peluso; Mansoureh Rezaei; Michael D Sintchak; Tina Talreja; Michael P Thomas; Tary Traore; Stepan Vyskocil; Gabriel S Weatherhead; Jie Yu; Julie Zhang; Lawrence R Dick; Christopher F Claiborne; Mark Rolfe; Joseph B Bolen; Steven P Langston
Journal:  Nature       Date:  2009-04-09       Impact factor: 49.962

9.  Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas.

Authors:  D Lallemand; J Manent; A Couvelard; A Watilliaux; M Siena; F Chareyre; A Lampin; M Niwa-Kawakita; M Kalamarides; M Giovannini
Journal:  Oncogene       Date:  2008-11-24       Impact factor: 9.867

10.  Localization to the cortical cytoskeleton is necessary for Nf2/merlin-dependent epidermal growth factor receptor silencing.

Authors:  Banumathi K Cole; Marcello Curto; Annie W Chan; Andrea I McClatchey
Journal:  Mol Cell Biol       Date:  2007-12-17       Impact factor: 4.272

View more
  8 in total

1.  Cellular prion protein (PrPC) in the development of Merlin-deficient tumours.

Authors:  L Provenzano; Y Ryan; D A Hilton; J Lyons-Rimmer; F Dave; E A Maze; C L Adams; R Rigby-Jones; S Ammoun; C O Hanemann
Journal:  Oncogene       Date:  2017-07-10       Impact factor: 9.867

Review 2.  Merlin: the wizard requires protein stability to function as a tumor suppressor.

Authors:  K Adam Morrow; Lalita A Shevde
Journal:  Biochim Biophys Acta       Date:  2012-06-30

3.  Inhibition of RUNX2 transcriptional activity blocks the proliferation, migration and invasion of epithelial ovarian carcinoma cells.

Authors:  Zhi-Qiang Wang; Mamadou Keita; Magdalena Bachvarova; Stephane Gobeil; Chantale Morin; Marie Plante; Jean Gregoire; Marie-Claude Renaud; Alexandra Sebastianelli; Xuan Bich Trinh; Dimcho Bachvarov
Journal:  PLoS One       Date:  2013-10-04       Impact factor: 3.240

4.  Novel age-dependent targets in vestibular schwannomas.

Authors:  Amos Toren; Juergen K Reichardt; Ali Andalibi; Nancy Ya-Hsuan Hsu; Joni Doherty; William Slattery; Ruty Mehrian-Shai
Journal:  Hum Genomics       Date:  2014-06-30       Impact factor: 4.639

Review 5.  The role and mechanism of CRL4 E3 ubiquitin ligase in cancer and its potential therapy implications.

Authors:  Youzhou Sang; Fan Yan; Xiubao Ren
Journal:  Oncotarget       Date:  2015-12-15

6.  Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.

Authors:  Kayleigh Bassiri; Sara Ferluga; Vikram Sharma; Nelofer Syed; Claire L Adams; Edwin Lasonder; C Oliver Hanemann
Journal:  EBioMedicine       Date:  2017-01-18       Impact factor: 8.143

7.  CRL4Mahj E3 ubiquitin ligase promotes neural stem cell reactivation.

Authors:  Phuong Thao Ly; Ye Sing Tan; Chwee Tat Koe; Yingjie Zhang; Gengqiang Xie; Sharyn Endow; Wu-Min Deng; Fengwei Yu; Hongyan Wang
Journal:  PLoS Biol       Date:  2019-06-06       Impact factor: 8.029

Review 8.  Schwann cell development, maturation and regeneration: a focus on classic and emerging intracellular signaling pathways.

Authors:  Luca Franco Castelnovo; Veronica Bonalume; Simona Melfi; Marinella Ballabio; Deborah Colleoni; Valerio Magnaghi
Journal:  Neural Regen Res       Date:  2017-07       Impact factor: 5.135

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.